Search results
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 1 day agoThis approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis, plaque psoriasis, and Crohn ...
Biogen Inc. (NASDAQ:BIIB) Shares Bought by FIL Ltd
ETF DAILY NEWS· 6 days agoFIL Ltd raised its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 936.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 656,502 shares of ...
Why Is My Skin So Itchy?
Verywell Health via Yahoo News· 3 days agoPruritus, or itchy skin, is a characteristic feature of many skin diseases and an unusual sign of some systemic diseases. It can be painful or...
Phantom Cell Lines Undermine Cancer Research Credibility
Medscape· 3 days agoThis superficiality was illustrated by an image, created by artificial intelligence, of a mouse with...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 18 hours agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
How Neuroscience Is Leading the Next Wave of Skin-Care Innovation
PopSugar· 19 hours agoNot to mention, aromatherapy uses scent to affect mood and CBD products bind to cannabinoid...
IgG4-Related Disease Affects Men More Often, More Severely
Medscape· 1 day agoA recent study highlighted sex-based differences in manifestations of IgG4-related disease.
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
Missouri Independent via Yahoo News· 4 days agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
How To Get Rid Of (And Prevent) Chin Acne
Women's Health via Yahoo News· 3 days agoChin acne can be caused by your diet, hygiene practices, hormones, and plenty of other factors. Experts explain how to fight and prevent it in the first...
Nektar Therapeutics (NASDAQ:NKTR) Director Sells $23,400.00 in Stock
ETF DAILY NEWS· 5 days agoNektar Therapeutics (NASDAQ:NKTR – Get Free Report) Director Robert Chess sold 19,500 shares of Nektar Therapeutics stock in a transaction on Friday, June 14th. The shares were sold at an average ...
